Every Form 4 that DBV Technologies S.A. (DBVT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DBVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DBVT filings page.
DBV Technologies S.A. Chief Medical Officer Mohideen Pharis reported a sale of 464 ordinary shares on July 29, 2026 at $2.70 per share. The shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units. After this transaction, Pharis directly held 144,531 ordinary shares, which may be represented by American Depositary Shares, each currently representing five ordinary shares.
DBV Technologies S.A. Chief Medical Officer Mohideen Pharis reported a small insider sale of company stock. On January 29, 2026, Pharis sold 534 ordinary shares of DBV Technologies at a price of $4.86 per share, primarily to satisfy withholding tax obligations linked to vesting restricted stock units. After this transaction, Pharis beneficially owned 144,995 ordinary shares, held directly. The filing also notes that DBV Technologies’ ordinary shares may be represented by American Depositary Shares, with each ADS currently representing five ordinary shares.
DBV Technologies S.A. insider filing shows major warrant restructuring by Baker Brothers–affiliated funds. On January 12, 2026, 667, L.P. and Baker Brothers Life Sciences, L.P. exercised 2,299,656 and 25,005,240 DBV Technologies BS Warrants at a strike price of EUR 1.5764, receiving an equal number of Second Pre-Funded Warrants. Each Second Pre-Funded Warrant is initially exercisable for 1.75 Ordinary Shares at an unpaid exercise price of EUR 0.01 per underlying share and may be exercised until April 7, 2035.
The Second Pre-Funded Warrants are subject to a “Second Pre-Funded Warrant Beneficial Ownership Limitation,” generally capping beneficial ownership at 9.99% of DBV’s outstanding Ordinary Shares, with potential increases up to 19.99% of shares and 24.99% of voting rights subject to regulatory conditions and a 61‑day waiting period. The transactions and resulting indirect pecuniary interests are reported for entities including 667, L.P., Baker Brothers Life Sciences, L.P., Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, and individuals Julian C. Baker and Felix J. Baker, who disclaim beneficial ownership except to the extent of their pecuniary interests.
DBV Technologies S.A. reported insider activity by Chief Medical Officer Mohideen Pharis involving new equity awards and small share sales. On November 21, 2025, he was granted 253,000 stock options with a $2.90 exercise price, expiring November 21, 2035, and 44,000 RSUs, with both awards vesting in four equal annual installments starting November 21, 2026, subject to continued service. He sold a total of 8,120 ordinary shares on November 20–21, 2025 at prices around $2.8800 and $2.7700 per share. After these transactions, he directly holds 145,529 ordinary shares. The company notes that some shares were sold to satisfy withholding tax obligations upon RSU vesting and that each American Depositary Share represents five ordinary shares.
DBV Technologies S.A. (DBVT) reported a Form 4 for its Chief Financial Officer, Virginie Boucinha, reflecting new equity compensation granted on 11/21/2025. She acquired 32,000 ordinary shares at a price of $0, representing ordinary shares underlying a restricted stock unit (RSU) award, bringing her directly held ordinary shares to 70,000. She also received an employee stock option for 192,000 ordinary shares with an exercise price of $2.9 and an expiration date of 11/21/2035. Both the RSUs and the option vest in four equal annual installments starting on November 21, 2026, contingent on her continued service with the company.
DBV Technologies S.A. (DBVT) reported an equity award to its Chief Commercial Officer on a Form 4 insider filing. On November 21, 2025, the officer received 55,000 ordinary shares through a restricted stock unit (RSU) award and 316,250 employee stock options with an exercise price of $2.9 per share. Both the RSUs and options vest in four equal annual installments starting on November 21, 2026, contingent on continued service. The options expire on November 21, 2035. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing five ordinary shares.
DBV Technologies S.A. (DBVT) reported a Form 4 insider transaction for its Chief Executive Officer and director. On 11/21/2025, the reporting person received an employee stock option grant to buy 964,000 ordinary shares of DBV Technologies.
The option has an exercise price of $2.9 per share, stated in U.S. dollars and based on converting euros at an exchange rate of $1.15154 to €1.00 as of November 21, 2025. These options are exercisable until 11/21/2035 and were fully reported as directly owned.
The option vests in four equal annual installments starting on November 21, 2026, as long as the executive continues to provide service through each vesting date. This filing reflects an equity-based compensation award rather than an open-market purchase or sale of shares.